Harnessing AI For Drug Development – UK's BenevolentAI And MRCT Link

The premise that artificial intelligence (AI) can help drug developers identify other uses for existing therapies – rather than making big outlays to find new ones - and also help to direct scientists to the most promising discoveries more quickly, lies behind a new collaboration between BenevolentAI and the UK life science medical research charity MRC Technology (MRCT).

BenevolentAI, which describes itself as the largest private AI company in Europe, has teamed up with MRCT to explore drug discovery opportunities using small molecules and antibodies. The collaboration will last at least two years and see BenevolentAI share disease targets identified with its 'machine learning' technology with the charity, which will undertake the needed chemistry to create a lead compound. That will then be progressed through preclinical and clinical stages by BenevolentAI. MRCT will also use BenevolentAI’s technology to validate potential targets in molecules or antibodies. The duo